The role of non-synonymous NPY gene polymorphism in the nitric oxide production in HUVECs

Biochemical and Biophysical Research Communications

Volumn 381, Issue 4, 2009, Pages 587-591

  Kaipio, Katja ^a   Vahlberg, Tero ^a   Suominen, Marianne ^a,b   Pesonen, Ullamari ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Atherosclerosis; Endothelial cells; Endothelial dysfunction; eNOS; L7P polymorphism; Neuropeptide Y; NO; Vascular function

Indexed keywords

MESSENGER RNA; NITRIC OXIDE;

ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; NEUROPEPTIDE Y GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN;

CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; LEUCINE; NEUROPEPTIDE Y; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; PROLINE; RNA, MESSENGER; UMBILICAL VEINS;

EID: 62649148262     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.02.094     Document Type: Article

References (21)

1. Karvonen M.K., Pesonen U., Koulu M., Niskanen L., Laakso M., Rissanen A., Dekker J.M., Hart L.M., Valve R., and Uusitupa M.I. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat. Med. 4 (1998) 1434-1437
2. Karvonen M.K., Valkonen V.P., Lakka T.A., Salonen R., Koulu M., Pesonen U., Tuomainen T.P., Kauhanen J., Nyyssonen K., Lakka H.M., Uusitupa M.I., and Salonen J.T. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 159 (2001) 145-151
3. Niskanen L., Karvonen M.K., Valve R., Koulu M., Pesonen U., Mercuri M., Rauramaa R., Toyry J., Laakso M., and Uusitupa M.I. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J. Clin. Endocrinol. Metab. 85 (2000) 2266-2269
4. Wallerstedt S.M., Skrtic S., Eriksson A.L., Ohlsson C., and Hedner T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J. Hypertens. 22 (2004) 1277-1281
5. Järvisalo M., Jartti L., Karvonen M., Pesonen U., Koulu M., Marniemi J., Hammar N., Kaprio J., Paakkunainen U., Simell O., Raitakari O., and Rönnemaa T. Enhanced endothelium-dependent vasodilation in subjects with Proline7 substitution in the signal peptide of neuropeptide Y. Atherosclerosis 167 (2003) 319-326
6. Pesonen U. Human NPY gene variants in cardiovascular and metabolic diseases. EXS (2006) 247-267
7. Ignarro L.J., and Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr. Atheroscler. Rep. 6 (2004) 281-287
8. Napoli C., de Nigris F., Williams-Ignarro S., Pignalosa O., Sica V., and Ignarro L.J. Nitric oxide and atherosclerosis: an update. Nitric Oxide 15 (2006) 265-279
9. Movafagh S., Hobson J., Spiegel S., Kleinman H., and Zukowska Z. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J. 20 (2006) 1924-1926
10. You J., Edvinsson L., and Bryan R.J. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries. J. Cereb. Blood Flow Metab. 21 (2001) 77-84
11. Lee E.W., Michalkiewicz M., Kitlinska J., Kalezic I., Switalska H., Yoo P., Sangkharat A., Ji H., Li L., Michalkiewicz T., Ljubisavljevic M., Johansson H., Grant D.S., and Zukowska Z. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J. Clin. Invest. 111 (2003) 1853-1862
12. Chen S.H., Fung P.C., and Cheung R.T. Neuropeptide Y-Y1 receptor modulates nitric oxide level during stroke in the rat. Free Radic. Biol. Med. 32 (2002) 776-784
13. Kallio J., Pesonen U., Kaipio K., Karvonen M.K., Jaakkola U., Heinonen O.J., Uusitupa M.I., and Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 15 (2001) 1242-1244
14. Silva A.P., Kaufmann J.E., Vivancos C., Fakan S., Cavadas C., Shaw P., Brunner H.R., Vischer U., and Grouzmann E. Neuropeptide Y expression, localization and cellular transducing effects in HUVEC. Biol. Cell. 97 (2005) 457-467
15. Bitran M., Tapia W., Eugenin E., Orio P., and Boric M.P. Neuropeptide Y induced inhibition of noradrenaline release in rat hypothalamus: role of receptor subtype and nitric oxide. Brain Res. 851 (1999) 87-93
16. Qiu W., Kass D.A., Hu Q., and Ziegelstein R.C. Determinants of shear stress-stimulated endothelial nitric oxide production assessed in real-time by 4,5-diaminofluorescein fluorescence. Biochem. Biophys. Res. Commun. 286 (2001) 328-335
17. Mitchell G.C., Wang Q., Ramamoorthy P., and Whim M.D. A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y. J. Neurosci. 28 (2008) 14428-14434
18. Ding B., Kull B., Liu Z., Mottagui-Tabar S., Thonberg H., Gu H.F., Brookes A.J., Grundemar L., Karlsson C., Hamsten A., Arner P., Ostenson C.G., Efendic S., Monne M., von Heijne G., Eriksson P., and Wahlestedt C. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul. Pept. 127 (2005) 45-53
19. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., Manuck S.B., Brown S.M., Hauger R.L., Stohler C.S., Zubieta J.K., and Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 452 (2008) 997-1001
20. Shah S.H., Freedman N.J., Zhang L., Crosslin D.R., Stone D.H., Haynes C., Johnson J., Nelson S., Wang L., Connelly J.J., Muehlbauer M., Ginsburg G.S., Crossman D.C., Jones C.J., Vance J., Sketch M.H., Granger C.B., Newgard C.B., Gregory S.G., Goldschmidt-Clermont P.J., Kraus W.E., and Hauser E.R. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet. 5 (2009) e1000318
21. Pesonen U. NPY L7P polymorphism and metabolic diseases. Regul. Pept. 149 (2008) 51-55